Topic: Drug Development for Ovarian Cancer: Challenges and Successes

Ursula Matulonis, MD is Chief and Director of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is a leader in developing innovative trials for ovarian cancer using PARP inhibitors, anti-angiogenic agents and immunotherapies. #OvarianCancer

Breakthroughs in Cancer seminar series is one of the highest-profile seminar series for translational and clinical scientists in oncology. The series brings national leaders in cancer research to Stanford’s campus and highlights innovations across the spectrum of basic, translational, clinical, and population science. #oncology #cancerresearch #sciencemedicine

Learn more about our Breakthroughs in Cancer seminar series: https://med.stanford.edu/cancer/train...

Learn more about the Stanford Cancer Institute: https://med.stanford.edu/cancer

Follow the Stanford Cancer Institute
LinkedIn:   / stanford-cancer  
Twitter:   / scidirector  
Instagram:   / stanford.cancer  

Subscribe to the Stanford Cancer Institute:    / @stanfordcancerinstitute